CTOs on the Move

NeuroVasc Technologies

www.neurovasctechnologies.com

 
NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroVasc Technologies raised $34M on 02/27/2020

Similar Companies

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Hansa Biopharma

We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

Southern Biotech Associates

Southern Biotech Associates is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Masonry Technology Inc

Masonry Technology Inc is a Moreno Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...